presigna
ENKOSign in

For Korean biotechs

Your company card, drafted from public sources. Check and correct it yourself.

Pharma BD teams in Korea and abroad with a subscription read your card all year round. Your checks and corrections appear with it if you consent to showing your submissions. Reviewing and correcting your company card and setting its disclosure scope are free.

Request your company card by email

Your email app opens. Send us your company name; we check it and send you a private link for your company. If you already received an email from Presigna, use the link in that email.

presigna.com/c/•••••••/

Corvana Bio fictional

Asset CRVN-117

  • Target and mechanismHER3-directed antibody-drug conjugate (ADC)Company siteCorrect
  • Development stageLead optimizationPreclinical (IND-enabling)PressCorrected
  • Existing licenses, optionsAnswer nowAnswer on requestAfter CDA is recordedNot answered
Reviewed0 / 3

What you do

One link to check, correct and set the scope.

Open your company link and mark each item correct, corrected or not shown. Set the disclosure scope for each question and submit; we review it and update your card. You can follow each step on your dashboard.

For each value from public sources

  • Correct
  • Corrected
  • Not shown

Disclosure scope for each open question

  • Answer now
  • Answer on request
  • After CDA is recorded
  • Not answered

What biotechs get first

You correct how your company is described.

  • We first build your company card from public information and send it to you.
  • Every item carries its source. When you check and correct it, we will help make your corrections the reference information on your company.
  • Your card is visible to pharma BD teams in Korea and abroad that hold a subscription, and to their AI lookup tools. Information you have not checked is marked 'not confirmed by the company'; your corrections and answers are shown only if you consent to showing your submissions. It is not published on the open web.
A card the company reviewed itself (example) fictional

Corvana Bio: company card

CRVN-117 · Stage
Preclinical (IND-enabling) · IND targeted for 1H 2027
CRVN-117 · Wanted from a partner
Phase 1 co-development; licensing outside Asia

Reviewed by the company · source for every value

What you get

Free and paid membership

Free membership Free

  • You review and correct your company card and set its disclosure scope yourself. You can also ask for the card to be excluded.
  • Your card is visible to pharma BD teams.
  • Answer pharma questions and accept meeting requests, with no limit on how many.
  • Receive interest alerts. We do not tell you which company.

Paid membership Per company

  • Answer drafts

    We draft answers to the questions you receive, based on your card and the answers you approved; you edit and approve them.

  • Answer readiness check

    Based on the 20 questions pharma asks in a review, we list the answers you should confirm and the non-confidential materials worth preparing.

  • Meeting arrangement

    We schedule the meetings pharma requests and you accept, and put the expected questions and the answers you confirmed on one page.

Paid membership does not change the order or scope in which pharma sees you.

Membership and prices are on the guide page behind your company link (in Korean).

How it works

We follow pharma's usual review order.

Pharma teams usually screen on public information first, send their own CDA form when they want more, and receive confidential materials after signing. Presigna does not change that order.

  1. 1

    Card review

    The biotech receives its company card, drafted by AI from public sources only, and reviews and corrects it itself.

  2. 2

    Disclosure scope

    Only for questions public sources leave empty, the company chooses: answer now, answer on request, after CDA is recorded, or not answered. Values already public are reviewed as correct, corrected, or not shown.

  3. 3

    Questions and answers

    Pharma BD teams that Presigna has checked and that pay for access, and their AI tools, read the card. When a question arrives on an 'answer on request' item, only an answer the company chooses to give and approves goes back.

  4. 4

    CDA signature

    When an access request arrives, the company approves it and authorized signers sign the CDA the usual way. Pharma does nothing beyond its usual signature confirmation email.

  5. 5

    Materials

    The biotech (or both sides) notes in Presigna that the CDA was signed, and the biotech sends materials directly.

Presigna's role

Presigna is not a party to the CDA and receives neither its text nor confidential materials.

How the CDA record works

When a CDA is recorded, Presigna keeps three things: a fingerprint of the signed copy (it shows later that a document is the same one, without keeping the document), the signature confirmation, and the time.

Request your company card.

Reviewing and correcting your company card and setting its disclosure scope are free.

Request your company card by email

Your email app opens. Send us your company name; we check it and send you a private link for your company. If you already received an email from Presigna, use the link in that email.